Medifast (MED) Liabilities and Shareholders Equity (2010 - 2026)

Medifast's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $252.0 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 9.99% year-over-year to $252.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 9.7% YoY) and the FY2025 annual result came in at $248.0 million, down 12.75% from the prior year.
• Liabilities and Shareholders Equity was $252.0 million for Q1 2026 at Medifast, up from $248.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $421.4 million in Q1 2022 and bottomed at $248.0 million in Q4 2025.
• A 5-year average of $303.8 million and a median of $302.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity advanced 29.12% — and 2023, when it retreated 23.69%.
• Medifast's Liabilities and Shareholders Equity stood at $316.2 million in 2022, then declined by 1.99% to $309.9 million in 2023, then retreated by 8.29% to $284.2 million in 2024, then fell by 12.75% to $248.0 million in 2025, then climbed by 1.64% to $252.0 million in 2026.
• Business Quant data shows MED's Liabilities and Shareholders Equity at $252.0 million in Q1 2026, $248.0 million in Q4 2025, and $268.2 million in Q3 2025.